Day: August 28, 2020

KBC Ancora closes financial year 2019/2020 with a profit of EUR 60.8 million

Written by Customer Service on August 28, 2020. Posted in Earnings Releases And Operating Results.

Regulated information, Leuven, 28 August 2020 (17.40 hrs CEST)KBC Ancora closes financial year 2019/2020 with a profit of EUR 60.8 millionKBC Ancora recorded a profit of EUR 60.8 million in the financial year 2019/2020, equivalent to EUR 0.78 per share. This compares with a profit of EUR 253.7 million in the previous financial year. The full-year result was determined by the income from the interim dividend received on the participating interest in KBC Group (EUR 77.5 million), operating costs (EUR 2.2 million) and interest charges (EUR 14.5 million). The result in the second half of the financial year was EUR -8.2 million, or EUR -0.11 per share.As announced on 2 April 2020, the Board of Directors of Almancora Société de gestion, statutory director of KBC Ancora, decided not to distribute an interim dividend in respect of the financial...

KBC Ancora sluit boekjaar 2019/2020 af met een winst van 60,8 miljoen euro.

Written by Customer Service on August 28, 2020. Posted in Earnings Releases And Operating Results.

Gereglementeerde informatie, Leuven, 28 augustus 2020 (17.40 CEST)KBC Ancora sluit boekjaar 2019/2020 af met een winst van 60,8 miljoen euro.KBC Ancora boekte in het afgelopen boekjaar 2019/2020 een winst van 60,8 miljoen euro, hetzij 0,78 euro per aandeel, tegenover een winst van 253,7 miljoen euro in het voorgaande boekjaar. Het resultaat van afgelopen boekjaar werd bepaald door de inkomsten van het interimdividend uit de participatie in KBC Groep (77,5 miljoen euro), werkingskosten (2,2 miljoen euro) en interestlasten (14,5 miljoen euro). Het resultaat van het laatste halfjaar van het boekjaar bedroeg -8,2 miljoen euro, hetzij -0,11 euro per aandeel.Zoals aangekondigd op 2 april 2020 heeft de Raad van Bestuur van Almancora Beheersmaatschappij, statutaire bestuurder van KBC Ancora beslist om over boekjaar 2019/2020 geen interim-dividend...

KBC Ancora clôture l’exercice 2019/2020 sur un bénéfice de 60,8 millions d’euros

Written by Customer Service on August 28, 2020. Posted in Earnings Releases And Operating Results.

Informations réglementées, Leuven, 28 août 2020 (17.40 CEST) KBC Ancora clôture l’exercice 2019/2020 sur un bénéfice de 60,8 millions d’eurosKBC Ancora a engrangé pour l’exercice écoulé (2019/2020) un bénéfice de 60,8 millions d’euros, soit 0,78 euro par action, contre un bénéfice de 253,7 millions d’euros lors de l’exercice précédent. Le résultat de l’exercice écoulé a été déterminé par les revenus du dividende intérimaire provenant de la participation dans KBC Groupe (77,5 millions d’euros), ainsi que par les frais de fonctionnement (2,2 millions d’euros) et les charges d’intérêts (14,5 millions d’euros). Le résultat des six derniers mois de l’exercice s’est établi à -8,2 millions d’euros, soit -0,11 euro par action.Comme annoncé le 2 avril 2020,...

Downing THREE VCT plc – Notice of AGM

Written by Customer Service on August 28, 2020. Posted in Public Companies.

Downing THREE VCT plcLEI: 2138008V2JDU2K6ZHF80Notice of AGM28 August 2020The Board of Downing THREE VCT plc announces that the Annual General Meeting (AGM) of the Company will be held as a closed meeting on 23 September 2020 at 11:15am.Due to the current concerns about holding public meetings, in order to ensure the safety of Shareholders, the Management team and the Directors, the Board has taken the decision to restrict attendance at the AGM solely to Directors of the Company.The Notice of the AGM is available on the Downing website at: www.downing.co.uk/assets/d3agm

Downing TWO VCT plc – Notice of AGM

Written by Customer Service on August 28, 2020. Posted in Public Companies.

Downing TWO VCT plcLEI: 213800HJGTPW7F8YEY55Notice of AGM28 August 2020The Board of Downing TWO VCT plc announces that the Annual General Meeting (AGM) of the Company will be held as a closed meeting on 23 September 2020 at 11:00am.Due to the current concerns about holding public meetings, in order to ensure the safety of Shareholders, the Management team and the Directors, the Board has taken the decision to restrict attendance at the AGM solely to Directors of the Company.The Notice of the AGM is available on the Downing website at: www.downing.co.uk/assets/d2agm

Chrysalic VCT plc – Transaction in Own Shares

Written by Customer Service on August 28, 2020. Posted in Public Companies.

Chrysalis VCT plcLEI: 2138009FVDWULSIOX404Transaction in Own Shares28 August 2020Chrysalis VCT plc announces that on 28 August 2020 the Company purchased the following shares for cancellation:

Vistin Pharma ASA: Mandatory notification of trade

Written by Customer Service on August 28, 2020. Posted in Public Companies.

Kjell-Erik Nordby, CEO of Vistin Pharma ASA, and a primary insider, has on Friday 28th of August 2020 sold 100 000 shares in Vistin Pharma ASA at an average price of NOK 16.28 per share. Following this transaction, Kjell-Erik Nordby holds 100 000 shares in Vistin Pharma ASA.

IH 140647 Niðurstöður fundar skuldabréfaeigenda

Written by Customer Service on August 28, 2020. Posted in Public Companies.

Tilkynning til Kauphallar 28. ágúst 2020Íslandshótel – IH 140647Fundur skuldabréfaeigenda sem haldinn var 28. ágúst 2020 samþykkti meðfylgjandi breytingar á skilmálum skuldabréfsins.Viðhengi2020 08 28 Tilkynning til kauphallar

Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients

Written by Customer Service on August 28, 2020. Posted in Public Companies.

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International Liver Congress (ILC). One patient out of four dosed with 5 billion or more cells had a complete response, which was reported previously. The data also demonstrate an acceptable safety profile in patients with hepatocellular carcinoma (HCC).“A complete response in a patient with advanced liver cancer, and the anti-tumor activity we have reported in other patients with an acceptable safety profile, to date, further support the continued investigation of ADP-A2AFP,” said Elliot Norry, Adaptimmune’s Chief Medical Officer. “We remain encouraged by the potential...

SNAIGĖ, AB: Significant EBITDA growth despite declining sales

Written by Customer Service on August 28, 2020. Posted in Public Companies.

According to unaudited consolidated data, Snaigė, AB, achieved a turnover of EUR 12.3 million in the first half of 2020, i.e. 22% lower than during the same period last year.According to Mindaugas Sologubas, CEO of Snaigė, AB, the decrease in sales is a consequence of the global pandemic and global quarantine. “Due to the restrictions imposed by the quarantine, the company’s factory in Alytus was forced to work at part capacity for a couple of months, some employees were in downtime,” said Sologubas. “There is a shortage of supply, as many of our suppliers are in the countries affected by the pandemic. As a result, we our production output much lower than what we had planned for this period.”Despite the lower unaudited consolidated turnover for the first half of the year, the company’s unaudited consolidated EBITDA increased...

Day: August 28, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals